Cocrystal Pharma
COCP
24 hedge funds and large institutions have $3.52M invested in Cocrystal Pharma in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
41% more capital inflows, than outflows
Capital inflows: $1.09M | Capital outflows: $773K
9% more funds holding
Funds holding: 22 → 24 (+2)
0.28% more ownership
Funds ownership: 4.43% → 4.71% (+0.28%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$484K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$401K |
| 3 |
Morgan Stanley
New York
|
+$59.6K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$40.4K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$38.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$330K |
| 2 |
Goldman Sachs
New York
|
-$152K |
| 3 |
Wasatch Advisors
Salt Lake City,
Utah
|
-$149K |
| 4 |
KeyBank National Association
Cleveland,
Ohio
|
-$110K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$14.5K |
COCP Hedge Fund Activity: Q3 2018 in Review
24 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q3 2018, worth a combined $3.52M — down 27% from $4.85M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new COCP positions and 2 closed out — a net gain of 3 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $484K. The largest seller was Millennium Management, cutting an estimated $330K.
- 24 institutional investors held Cocrystal Pharma (COCP) as of Q3 2018, up from 22 in Q2 2018.
- Funds reported $3.52M of Cocrystal Pharma stock for Q3 2018, down 27% quarter-over-quarter.
- 5 funds opened new Cocrystal Pharma positions in Q3 2018 and 2 closed out, a net change of +3 holders.
- The largest Cocrystal Pharma buyer in Q3 2018 was Vanguard Group, an estimated $484K added.
- The largest Cocrystal Pharma seller in Q3 2018 was Millennium Management, an estimated $330K sold.
Based on aggregated 13F filings for Q3 2018.